Phase II trial of topotecan in patients with advanced renal cell carcinoma Journal Article

  


Authors: Murray Law, T.; Ilson, D. H.; Motzer, R. J.
Article Title: Phase II trial of topotecan in patients with advanced renal cell carcinoma
Abstract: Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma. © 1994 Kluwer Academic Publishers.
Keywords: adult; clinical article; aged; aged, 80 and over; clinical trial; neutropenia; advanced cancer; antineoplastic agents; topotecan; neoplasm staging; metastasis; phase 2 clinical trial; anemia; bone marrow suppression; gastrointestinal symptom; thrombocytopenia; camptothecin; drug screening; renal cell carcinoma; kidney carcinoma; kidney neoplasms; carcinoma, renal cell; drug response; intravenous drug administration; middle age; bone marrow diseases; human; male; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
Journal Title: Investigational New Drugs
Volume: 12
Issue: 2
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1994-06-01
Start Page: 143
End Page: 145
Language: English
DOI: 10.1007/bf00874445
PROVIDER: scopus
PUBMED: 7860232
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028054333&doi=10.1007%2fBF00874445&partnerID=40&md5=c8f9ba1182eeedaeff5ca8561281076a
Notes: Export Date: 14 January 2019 -- Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. David H Ilson
    433 Ilson
Related MSK Work